Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

ABSTRACT:

Introduction

IFN-beta is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are nonresponders) and requires a long treatment duration for accurate assessment to be possible. Information about genetic variations that predict responsiveness would allow appropriate treatment selection early after diagnosis, improve patient care, with time saving consequences and more efficient use of resources.

Materials & methods

We analyzed 61 SNPs in 34 candidate genes as possible determinants of IFN-beta response in Irish multiple sclerosis patients. Particular emphasis was placed on the exploration of combinations of allelic variants associated with response to therapy by means of a Markov chain Monte Carlo-bas

SUBMITTER: O'Doherty C 

PROVIDER: S-EPMC2727921 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature